TY - JOUR
T1 - Novel Therapies in Myeloproliferative Neoplasms (MPN)
T2 - Beyond JAK Inhibitors
AU - Economides, Minas P.
AU - Verstovsek, Srdan
AU - Pemmaraju, Naveen
N1 - Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Purpose of Review: With increased understanding of the pathobiology of myeloproliferative neoplasms (MPNs), multiple new agents are now being investigated. We aim to cover some of the current treatment options for MPNs and discuss new agents in development. Recent Findings: The introduction of ruxolitinib improved the treatment of many patients with intermediate and higher risk myelofibrosis. However, ruxolitinib monotherapy does not benefit all patients, and not all patients can receive this therapy due to limiting cytopenias. The unraveling of new molecular abnormalities and cellular pathways led to the development of several novel targeted agents that are currently under investigation in clinical trials. These agents have different mechanisms of action and are being used either alone or in combination with ruxolitinib. Summary: Novel targets include inhibition of apoptosis, the tumor microenvironment, telomerase enzyme action, immunotherapy, and fibrosis with associated cytokines. We comprehensively review and summarize the available preclinical and clinical trials with novel agents for MPNs.
AB - Purpose of Review: With increased understanding of the pathobiology of myeloproliferative neoplasms (MPNs), multiple new agents are now being investigated. We aim to cover some of the current treatment options for MPNs and discuss new agents in development. Recent Findings: The introduction of ruxolitinib improved the treatment of many patients with intermediate and higher risk myelofibrosis. However, ruxolitinib monotherapy does not benefit all patients, and not all patients can receive this therapy due to limiting cytopenias. The unraveling of new molecular abnormalities and cellular pathways led to the development of several novel targeted agents that are currently under investigation in clinical trials. These agents have different mechanisms of action and are being used either alone or in combination with ruxolitinib. Summary: Novel targets include inhibition of apoptosis, the tumor microenvironment, telomerase enzyme action, immunotherapy, and fibrosis with associated cytokines. We comprehensively review and summarize the available preclinical and clinical trials with novel agents for MPNs.
KW - JAK inhibitors
KW - Myeloproliferative neoplasms
KW - Novel drugs
KW - Novel therapies
KW - Ruxolitinib
UR - http://www.scopus.com/inward/record.url?scp=85074735210&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074735210&partnerID=8YFLogxK
U2 - 10.1007/s11899-019-00538-4
DO - 10.1007/s11899-019-00538-4
M3 - Review article
C2 - 31372878
AN - SCOPUS:85074735210
SN - 1558-8211
VL - 14
SP - 460
EP - 468
JO - Current hematologic malignancy reports
JF - Current hematologic malignancy reports
IS - 5
ER -